微创医疗(00853)2021年中报点评：业绩符合预期，创新器械业务高速增长

国泰君安2021-09-01

本报告导读：公司2021年中报业绩符合预期，介入瓣膜、神经介入、主动脉及外周介入等创新业务高速增长，维持增持评级。业绩符合预期，维持增持评级。公司2021H1实现收入3.85亿美元，同比增长17.7%(剔除汇率影响)。研发投入持续增加，归母净利润-0.90亿美元。毛利率为64.4%，低于2020H1的70.9%，主要系冠脉支架带量采购影响，业绩符合预期。维持2021-2023年预测EPS-0.11...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

TabFnlk
2021-09-02
TabFnlk
窜天猴。。。点燃

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2164737899?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36","is_english":false,"pubTime":"2021-09-01 17:19","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2164737899","market":"hk","top_or_hot":-1,"title":"微创医疗(00853)2021年中报点评：业绩符合预期，创新器械业务高速增长","media":"国泰君安","content":"<div>\n<p>本报告导读：公司2021年中报业绩符合预期，介入瓣膜、神经介入、主动脉及外周介入等创新业务高速增长，维持增持评级。业绩符合预期，维持增持评级。公司2021H1实现收入3.85亿美元，同比增长17.7%(剔除汇率影响)。研发投入持续增加，归母净利润-0.90亿美元。毛利率为64.4%，低于2020H1的70.9%，主要系冠脉支架带量采购影响，业绩符合预期。维持2021-2023年预测EPS-0.11...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202109011732467c36ec6a&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>微创医疗(00853)2021年中报点评：业绩符合预期，创新器械业务高速增长</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n微创医疗(00853)2021年中报点评：业绩符合预期，创新器械业务高速增长\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-01 17:19 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202109011732467c36ec6a&s=b><strong>国泰君安</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>本报告导读：公司2021年中报业绩符合预期，介入瓣膜、神经介入、主动脉及外周介入等创新业务高速增长，维持增持评级。业绩符合预期，维持增持评级。公司2021H1实现收入3.85亿美元，同比增长17.7%(剔除汇率影响)。研发投入持续增加，归母净利润-0.90亿美元。毛利率为64.4%，低于2020H1的70.9%，主要系冠脉支架带量采购影响，业绩符合预期。维持2021-2023年预测EPS-0.11...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202109011732467c36ec6a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00853","symbol_name":"微创医疗","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202109011732467c36ec6a&s=b","article_id":"2164737899","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36"],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202109011732467c36ec6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2164737899","pubTimestamp":1630487952,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"业绩符合预期，维持增持评级。分业务看，冠脉支架产品中标后扩大市场份额，但未弥补价格下降损失，心血管介入产品收入66.8百万美元，同比下降29.9%，海外冠脉支架销售仍受疫情影响；骨科收入110.1百万美元，同比增长22.9%，其中国际、国内分别增长20.9%、37.5%；心律管理业务收入108.3百万美元，同比增长20.0%，其中国际、国内分别增长17.3%、95%。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"00853":"微创医疗"},"translate_title":"MicroPort Scientific (00853) 2021 Interim Report Review: The performance is in line with expectations, and the innovative equipment business is growing rapidly","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00853":1},"content_text":"本报告导读：公司2021年中报业绩符合预期，介入瓣膜、神经介入、主动脉及外周介入等创新业务高速增长，维持增持评级。业绩符合预期，维持增持评级。公司2021H1实现收入3.85亿美元，同比增长17.7%(剔除汇率影响)。研发投入持续增加，归母净利润-0.90亿美元。毛利率为64.4%，低于2020H1的70.9%，主要系冠脉支架带量采购影响，业绩符合预期。维持2021-2023年预测EPS-0.11/-0.06/0.01美元，维持目标价8.90美元，折合69.25元港币，维持增持评级。冠脉业务仍受带量采购影响，骨科及心律管理业务恢复性增长。分业务看(剔除汇率影响)，冠脉支架产品中标后扩大市场份额，但未弥补价格下降损失，心血管介入产品收入66.8百万美元，同比下降29.9%，海外冠脉支架销售仍受疫情影响；骨科收入110.1百万美元，同比增长22.9%，其中国际、国内分别增长20.9%、37.5%；心律管理业务收入108.3百万美元，同比增长20.0%，其中国际、国内分别增长17.3%、95%。创新业务快速放量。大动脉及外周血管介入产品收入55.8百万美元，同比增长68.6%；神经介入收入25.4百万美元，同比增长114.5%；心脏瓣膜收入13.4百万美元，同比增长121.8%，VitaFlow覆盖超过220家医院，前20大TAVI医院已进入19家；手术 机器人 业务蜻蜓眼机器人已上市，图迈、鸿鹄已向NMPA提交注册申请。创新器械产业可以带来正外部性，公司契合产业变革方向。公司继续坚持创新投入，H1研发投入117.1百万美元，占收入比例为30.4%，大量创新产品积极推进，并布局非血管介入、运动医学、辅助生殖、康复医学、内分泌、医学美容等新兴业务领域。中国人口老龄化趋势下，国产创新器械是可以带来正外部性的产业，也是国家长期重点鼓励扶持的产业，微创医疗是一家极具开拓创新意识与前瞻眼光的医疗器械平台型公司，契合产业变革方向。其核心竞争力是高胜率孵化优质创新子公司的能力，有望持续保持稳健增长，投资微创相当于以接近Pre-IPO的阶段投资中国医疗器械行业未来的新兴赛道，综合抗风险能力更强。风险提示：带量采购降价超预期，研发不及预期，商业化不及预期风险。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":812815325,"gmtCreate":1630572703067,"gmtModify":1630572703067,"author":{"id":"3544606489804355","authorId":"3544606489804355","name":"TabFnlk","avatar":"https://static.tigerbbs.com/85ffd07624617a0ec8c253836967ae8b","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"窜天猴。。。点燃","listText":"窜天猴。。。点燃","text":"窜天猴。。。点燃","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812815325","repostId":2164737899,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2164737899"}